141 related articles for article (PubMed ID: 22509668)
1. [Promising on advanced cancer, several new drugs coming].
Widmark A; Karlsson CT
Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
[No Abstract] [Full Text] [Related]
2. New agents in the arsenal to fight castrate-resistant prostate cancer.
Ezzell EE; Chang KS; George BJ
Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
[TBL] [Abstract][Full Text] [Related]
3. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
4. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
5. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
6. New prostate cancer drugs hold promise.
Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
[No Abstract] [Full Text] [Related]
7. Advanced clinical states in prostate cancer.
Cheng HH; Lin DW; Yu EY
Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
[TBL] [Abstract][Full Text] [Related]
8. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
9. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
[TBL] [Abstract][Full Text] [Related]
11. A new era for castrate resistant prostate cancer: a treatment review and update.
Fong MK; Hare R; Jarkowski A
J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
[TBL] [Abstract][Full Text] [Related]
12. [Strategy in advanced castration-resistant prostate cancer].
Gross-Goupil M; Roca S; Pasticier G; Ravaud A
Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone and castration-resistant prostate cancer.
Burki TK
Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
[No Abstract] [Full Text] [Related]
14. [2017 ASCO: Complete androgen blockade strikes back].
Penel N
Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
[No Abstract] [Full Text] [Related]
15. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
17. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
D'Amico AV
J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
[No Abstract] [Full Text] [Related]
18. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Tanimoto T; Hori A; Kami M
N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392
[No Abstract] [Full Text] [Related]
19. Managing advanced prostate cancer: the rapidly changing treatment landscape.
Dreicer R
Am J Manag Care; 2014 Dec; 20(12 Suppl):S282-9. PubMed ID: 25734964
[TBL] [Abstract][Full Text] [Related]
20. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
Armstrong AJ
Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
